chemical rearrangement of further glycation for months. Glycated albumin has been shown to play a critical role in atherogenesis by inducing inflammatory mediators in the vessel wall, as well as the proliferation and migration of vascular smooth muscle cells. 11 Recent studies indicate that glycated albumin causes parallel dose-dependent induction of nuclear factor-B, 12 increased inducible nitric oxide synthase mRNA expression and total nitric oxide synthase activity, and significantly enhances apoptosis of endothelial cells, 13 suggesting that an increased serum level of glycated albumin may be associated with development of coronary artery disease (CAD). Determination of the serum level of glycated albumin, besides assessing the degree of glycemic control, to some extent may reflect the status of other AGEs, the in-vivo glycation load and even more, an accelerated process of inflammation and oxidative stress in diabetic patients, especially those complicated with CAD. This study was conducted to explore the relationship between the serum level of glycated albumin and the presence and severity of CAD in patients with type 2 DM (T2DM).
Methods

Study Population
A total of 320 consecutive patients with T2DM, who underwent coronary angiography for the diagnosis of CAD in the Department of Cardiology, Shanghai Rui Jin Hospital, were included. Hypertension was defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg, and hyperlipidemia was diagnosed according to guideline of the National Cholesterol Education Program (ATP III). T2DM was diagnosed using the American Diabetes Association criteria. Renal insufficiency was defined by serum creatinine concentration >133 mol/L (1.5 mg/dl). Those with type 1 DM, acute coronary syndrome, previous myocardial infarction and other inflammation-related diseases were excluded. The protocol was approved by the hospital's Ethics Committee and written informed consent was given by all patients.
Coronary Angiography
Coronary arteriography was performed using standard Judkins techniques or a radial approach. Angiographic analysis was carried out by 2 experienced interventional cardiologists, who were unaware of the study protocol. Significant CAD was defined as the presence of luminal diameter stenosis ≥70% in the left anterior descending artery or its first diagonal branch, left circumflex artery or its first obtuse marginal branch, and right coronary artery. Left main stenosis (≥50% luminal narrowing) was considered as 2-vessel disease. In accordance with lesion severity previously correlated with reduced coronary flow reserve and with the clinical standards recognized in the American College of Cardiology/American Heart Association guidelines for coronary angiography, patients with severe disease had at least 1 coronary artery stenosis of ≥70%.
For the purpose of this study, patients were divided into 4 groups based on the visual angiographic results: control group consisted of 83 patients with normal coronary arteries, Group I comprised 51 patients with 1-vessel disease, Group II included 80 patients with 2-vessel disease, and Group III had 106 patients with 3-vessel disease. The severity of CAD was expressed as the number of diseased coronary arteries.
Biochemical Investigations
Blood samples were collected after overnight fasting and stored at -70°C prior to analysis. Admission glucose concentrations were assessed immediately after admission. Serum total cholesterol and triglyceride levels were measured by automated enzymatic procedures (Hoffman-La Roche, Basel, Switzerland). The low-density lipoproteincholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C) and lipoprotein (Lp) (a) levels were determined after separating the lipoprotein fractions from fresh fasting sera by sequential ultracentrifugation. Concentrations of apolipoproteins A (apoA) and B (apoB) were measured by immunoturbidimetric methods using commercial kit (Boehringer-Mannheim, Mannheim, Germany). Serum concentrations of hemoglobin A1c (HbA1c), blood urea nitrogen, creatinine, and uric acid were assessed using standard methods. The serum glycated albumin level was measured with the improved bromocresol purple method using the Lucica TM glycated albumin-L assay kit (Asahi Kasei Pharma, Japan). Its linear range was 3.2-68.1% and the maximum intra-and interassay CV was 1.2% and 3.0%, respectively. Serum tumor necrosis factor (TNF)-level was assessed using Human TNF-/TNFSF1A Quantikine ELISA kit (R & D systems, USA) with an intra-and interassay CV of <5.4% and <7.4%, respectively.
Statistical Analysis
All statistical analyses were performed using SPSS for Windows 13.0 (SPSS Inc, Chicago, IL, USA). Data are presented as frequencies and percentages for categorical variables and mean ± SD for continuous variables, unless otherwise indicated. Data of TNF-measurement were logarithmically transformed and an analysis of variance (ANOVA) was performed. Differences between 2 groups were assessed using the Chi-square and unpaired t-tests. Because glycated albumin, triglycerides, Lp(a) and creatinine values were not normally distributed, between-group differences were assessed by the Mann-Whitney U-test. Correlation between continuous variables was determined by Pearson correlation coefficients. Spearman correlations were used to test the relationship between the serum levels of glycated albumin and HbA1c and severity of CAD (control group was defined as 0-vessel disease). Binary and multinomial logistic regression analysis was performed to identify the relative risk of the serum glycated albumin level for the presence and severity of CAD, expressed as odds ratios (OR) with 95% confidence intervals (CI). The predictive values of glycated albumin and HbA1c for the presence of CAD were calculated by constructing receiver-operating characteristic (ROC) curves. To establish independent determinants of glycated albumin, multivariate stepwise linear regression analysis was made with glycated albumin as a dependent variable control for glucose, age, blood pressure, cholesterol, triglycerides, Lp(a), blood urea nitrogen, creatinine, uric acid, and TNF-. A value of p<0.05 was considered statistically significant.
Results
Clinical Characteristics
Diabetic patients with CAD were older, and more were male and cigarette smokers compared with the controls (Table 1 In addition, most of the diabetic patients in the control group and the patients with T2DM and CAD were receiving statin medication (62.7% vs 73.4%, p>0.05), and did not differ significantly with respect to the use of peroxisome proliferators-activated receptor gamma agonists (13.3% vs 18.1%, p>0.05) and insulin (30.1% vs 41.4%, p>0.05), nor did it among patients of Groups I-III (data not show). There was no difference in treatment with other antidiabetic agents in diabetic patients with and without CAD.
Serum Glycated Albumin, HbA1c and TNF-Levels
Serum glycated albumin and TNF-levels were significantly higher in patients with CAD than in the controls, but the serum HbA1c levels did not significantly differ (Table 1) . There was a significant difference between Group I and III in the serum glycated albumin levels (19.5±3.3% vs 21.8± 5.7%, p<0.001), but there was no significant difference in the HbA1c and TNF-levels among the 3 CAD groups (Fig 1) . Serum glycated albumin and TNF-levels correlated significantly with the number of diseased coronary arteries (Spearman r=0.205, p<0.001 and r=0.148, p=0.01), but the serum HbA1c level was not significantly related to the severity of CAD (Spearman r=0.105, p=0.059).
Relationship Between Glycated Albumin and Other Biochemical Parameters
Univariate analysis showed that the serum glycated albumin level was closely related to the serum admission glucose (r=0.495, p<0.001) and HbA1c (r=0.795, p<0.001) levels, and correlated significantly with the serum levels of TNF-(r=0.123, p=0.028), blood urea nitrogen (r=0.167, p=0.004), and triglycerides (r=0.129, p=0.021) (Fig 2) , but not with the LDL and Lp(a) levels. In the final multivariate linear regression analysis model that explained 29.2% (adjusted multiple R 2 =0.292) of the variation in glycated albumin, the independent determinants were admission glucose (p<0.0001), TNF-(p=0.001), blood urea nitrogen (p=0.004) and triglycerides (p=0.035) ( Table 2) . Multivariate analysis for independent determinants of coronary artery disease (CAD) and 3-vessel disease. Male gender, older age, glycated albumin and lipoprotein (Lp) (a) were independent risk factors for CAD, and glycated albumin and Lp(a) were for 3-vessel disease.
Binary and Multinomial Logistic Regression Analysis
Male gender, older age (≥65 years), glycated albumin and Lp(a) were found to be independent risk factors for the presence of CAD in diabetic patients, glycated albumin ≥19% and Lp(a) ≥0.22 g/L having OR 2.9 (p<0.001) and 2.29 (p=0.01), respectively. When using 1-vessel disease as the reference group, glycated albumin ≥21% (OR 2.3, p=0.032) and Lp(a) ≥0.30 g/L (OR 3.312, p=0.011) were independent predictors for 3-vessel disease (Fig 3) .
ROC Curve for Glycated Albumin and HbA1c in Predicting CAD in T2DM
The area under the ROC curve for glycated albumin (0.620, 95%CI 0.548 to 0.691, p=0.001) was superior to that for HbA1c (0.543, 95%CI 0.473 to 0.613, p=0.243) (Fig 4) .
Discussion
Serum Level of Glycated Albumin Predicts the Presence and Severity of CAD
Gycated albumin represents the largest fraction of circulating glycated proteins (≈80% of total) in vivo. Recent studies indicate that glycated albumin activates nuclear factor-B and the extracellular signal-regulated kinases/ c-Fos/activating protein-1 pathway, leading to induction of monocyte chemoattractant protein-1 and interleukin-6 gene expression and stimulation of cell proliferation and migration. 11 That suggests glycated albumin plays an important role in the occurrence and acceleration of atherosclerosis in DM. 14 In the present study, glycated albumin ≥19% was found to be an independent predictor for the presence of CAD (OR 2.9; p<0.001) in diabetic patients. Atherosclerosis is a chronic condition, commencing in youth, and as up to 30% of diabetic patients with CAD have silent ischemia, 15 surrogate measures of vascular disease are crucial for early identification of diabetic patients with vascular damage and for monitoring the efficacy of interventions. Determination of the serum glycated albumin level seems to be an alternative option, enabling a reduction in the economic burden of detecting vascular complications. Furthermore, in the present study the ROC plot also demonstrated that the serum glycated albumin level was a significant predictor for the presence of CAD (p=0.001), whereas HbA1c was not (p=0.243). Spearman correlation analysis showed that the serum level of glycated albumin (Spearman r=0.205, p<0.001) correlated positively with the number of significantly diseased coronary vessels, indicating a pronounced proatherogenic effect of an increased serum level of glycated albumin, which is consistent with previous findings. 12, 13 Furthermore, logistic regression analysis revealed that glycated albumin was also an independent predictor for the severity of CAD, and a serum level of glycated albumin ≥21% has been consistently associated with a 2.3-fold (95%CI 1.075 to 4.922, p=0.032) increase in risk of progressing to 3-vessel disease when compared with a serum glycated albumin level <21%. These results indicate that inhibition of in-vivo glycated albumin is important for the prevention of CAD in patients with T2DM. In the current study, Lp(a) was found to be an independent risk factor for the presence and severity of CAD, whereas traditional risk factors such as HDL-C and LDL-C were not. This may be explained by the fact that majority of the study patients had been receiving lipid-lowering agents. However, there have been less effective medications for lowering the serum Lp(a) level, and Lp(a) is less sensitive to statin treatment.
Independent Determinants of Glycated Albumin
In this study, univariate analysis showed that glycated albumin correlated significantly with the serum level of admission glucose, TNF-, blood urea nitrogen, and triglycerides. In order to establish a strategy of reducing the serum concentration of glycated albumin, we examined the independent determinants of glycated albumin using multivariate stepwise linear regression analyses. In the last model, the serum level of glucose was the most significant, but not the sole, independent determinant for glycated albumin, and serum levels of TNF-, blood urea nitrogen and triglycerides were also independently related to glycated albumin in diabetic patients with CAD, which is consistent with previous findings. 16, 17 The association between the serum level of blood urea nitrogen and glycated albumin is mostly explained by the accumulation of reactive carbonyl compounds, 18 oxidative stress and inflammation 19 in renal insufficiency. Anderson et al reported that inflammation activates myeloperoxidase pathways, resulting in AGEs formation. 20 Therefore, the inflammatory process may, at least partly, play a role in the formation of glycated albumin in diabetic patients with CAD. Our results indicate that intensive glycemic control may be not sufficient to inhibit glycated albumin in diabetic patients complicated with atherosclerosis, thus control of the inflammatory process is at least equally important as glycemic control for preventing the formation of glycated albumin in these patients. In the present study, the variables in the multivariate linear regression model only explained 29.2% of the variation in the serum level of glycated albumin. Thus, further research is required to find other determinants, the most likely of which will be those related to oxidative stress because of its involvement in AGEs formation. 21 
Relationship Between Glycated Albumin and HbA1c
In this study, a significant correlation was found between the glycated albumin and HbA1c values (r=0.795, p<0.001), indicating that determination of the serum glycated albumin level may be a valuable adjunct to HbA1c measurement for evaluating short-term glycemic control in diabetic patients. In addition, our results demonstrated a close association between the serum glycated albumin level and the number of diseased coronary arteries, but the Spearman correlation between HbA1c and severity of CAD did not reach statistical significance level (r=0.105, p=0.059). Our results are different from previous findings that showed a significant increasing trend of HbA1c level over the increasing number of significantly stenotic coronary vessels, 22 which may be explained by the relative small sample size in our study and the different diagnostic criteria of significant CAD. Furthermore, the ROC curve indicated glycated albumin may be a valuable predictor for predicting CAD in T2DM, but that the serum HbA1c level was not.
Strategy for Controling Glycated Albumin and Inflammation
Inflammation of the vessel wall is closely associated with coronary atherosclerosis, 23, 24 and glycated albumin and AGEs are involved in a vicious cycle of inflammation, generation of reactive oxygen species and amplification of AGEs production, thereby promoting atherogenesis. 12, 14, 20, 25 The current study showed that both the admission glucose level and the serum TNF-level were major independent determinants for glycated albumin, so intensive control of both the inflammatory process and hyperglycemia may be crucial in the prevention of atherosclerosis in patients with DM. Previous studies have demonstrated that peroxisome proliferators-activated receptor gamma activators, such as pioglitazone and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), have lead to substantial glycemic improvement and reduction of inflammation, [26] [27] [28] indicating that both agents might be useful in preventing the initiation and progression of CAD, especially in diabetic patients.
Study Limitations
This was a retrospective study, and the sample size was relatively small, thus some subgroup comparisons may have lacked power to detect significant differences for select variables. The classification of significant CAD based on visual estimation of angiographic stenosis of coronary artery lesions at ≥70% is admittedly arbitrary. However, within the range of angiographically significant CAD, including lesions of ≥70%, this criteria of severity correlates well with physiologic significance, has relevance to commonly applied angiographic standards and is widely accepted clinical practice. 29, 30 In addition, glycated albumin displayed only 10% increase (from 19.4% to 21.2%), although its mean value differed statistically significant between diabetic patients with and without CAD. This may make the measurement of glycated albumin itself very difficult to use as a daily laboratory test. However, detection of serial changes in the serum glycated albumin level may have value for predicting the progression of pathology in diabetic patients during close follow-up. Likewise, glycated albumin is only a type of early stage AGEs, and as previous studies have shown that some 'traditional' AGEs (eg, N -[carboxymethl] lysine and S100) are associated with vascular complications in diabetic patients, the relationship between these AGEs and the presence and severity of CAD needs further investigation.
Conclusions
The present study demonstrated that the serum level of glycated albumin is associated with the presence and severity of CAD in patients with T2DM. Glycated albumin is mainly determined by the serum levels of glucose and TNF-. Further studies are warranted to examine if intensive inhibition of in-vivo glycated albumin and inflammation has a substantial impact on CAD development in diabetic patients.
